Virus cocktail targets superbug pneumonia in first human test
NCT ID NCT07492771
First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This early-stage trial tests MP101, a mix of two viruses that attack bacteria (phages), in 18 adults with Pseudomonas aeruginosa pneumonia. Participants receive a single dose of MP101 or a placebo alongside standard antibiotics. The main goal is to check safety and how the body handles the treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MP101 (a cocktail of two bacteriophages)
- What this could lead to
- If successful, this could point toward a new treatment option for hard-to-treat Pseudomonas pneumonia, especially when antibiotics fail.
- What could go wrong
- This is a very early, small phase 1 trial with only 18 participants. The main goal is safety, not effectiveness, and it may not work or have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PSEUDOMONAS AERUGINOSA PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Severance Hospital
RECRUITINGSeoul, Seodaemun-gu, 03722, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Does the setting of care affect whether kids finish their antibiotics?
- Blood cancer patients may need higher antibiotic doses to beat superbugs
- Inhaled antibiotics aim to beat pneumonia in ECMO patients
- Which works better: one antibiotic or two for this superbug?
- One-Hour test could revolutionize pneumonia treatment in hospitals